Stockscreener 앱 받기
0.7501
2.56%
0.0188
전일 마감가:
$0.7313
열려 있는:
$0.73
하루 거래량:
504.47K
Relative Volume:
0.31
시가총액:
$93.31M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.2885
EPS:
-2.6
순현금흐름:
$-175.17M
1주 성능:
-2.30%
1개월 성능:
-3.72%
6개월 성능:
-45.65%
1년 성능:
-53.41%
1일 변동 폭
$0.72
$0.7567
1주일 범위
$0.72
$0.7751
52주 변동 폭
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
0.7501 | 93.31M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.21 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.43 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
552.88 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.02 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
Coherus Biosciences Rebrands to Coherus Oncology - TipRanks
Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus
Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com
Coherus Completes Strategic Transformation to Coherus - GlobeNewswire
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovative Therapies | CHRS Stock News - GuruFocus
First patient dosed in STORM-Coherus cancer alliance - Business Weekly
Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Announces Clinical Collaboration with STORM - GlobeNewswire
Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com
StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World
The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey
Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks
Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus
Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN
Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus
Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus
Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.31%
0.62%
자본화:
|
볼륨(24시간):